Company: EDSA
Filing Date: 2025-12-12
Form Type: 10-K
Source: 0001171843-25-007914
Chunk: 227

Company: Edesa Biotech, Inc.
Filing Date: 2025-12-12
Form: 10-K
Item: Item 1
Chunk 227
---

			Corporate Secretary (Principal Executive Officer)

			/s/ Peter Weiler

			Chief Financial Officer

			December 12, 2025

			Peter Weiler

			(Principal Financial and Accounting Officer)

			/s/ Joan Chypyha

			Director

			December 12, 2025

			Joan Chypyha

			/s/ David Liu

			Director

			December 12, 2025

			David Liu

			/s/ Sean MacDonald

			Director

			December 12, 2025

			Sean MacDonald

			/s/ Patrick Marshall

			Director

			December 12, 2025

			Patrick Marshall

			/s/ Charles Olson

			Director

			December 12, 2025

			Charles Olson

			/s/ Carlo Sistilli

			Chairman of the Board of Directors

			December 12, 2025

			Carlo Sistilli

75

EDESA BIOTECH, INC.

INDEX TO FINANCIAL STATEMENTS

			Page

			Report of Independent Registered Public Accounting Firm – MNP LLP, Toronto Canada, PCAOB ID 1930

			F-2

			Consolidated Balance Sheets at September 30, 2025 and 2024

			F-4

			Consolidated Statements of Operations and Comprehensive Loss for the years ended September 30, 2025 and 2024

			F-5

			Consolidated Statements of Cash Flows for the years ended September 30, 2025 and 2024

			F-6

			Consolidated Statements of Changes in Shareholders’ Equity for the years ended September 30, 2025 and 2024

			F-7

			Notes to Consolidated Financial Statements

			F-8

F-1

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and Shareholders of Edesa Biotech, Inc.

Opinion on the Consolidated Financial Statements

We have audited the accompanying consolidated balance sheets of Edesa Biotech, Inc. (the “Company") as of September 30, 2025 and 2024, and the related consolidated statements of operations and comprehensive loss, changes in shareholders’ equity, and cash flows for each